Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)

NCT03979638 is registered in ClinicalTrials.gov with Bellus Health Inc. - a GSK company as lead sponsor.

NCT NCT03979638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)
Lead sponsor
Bellus Health Inc. - a GSK company
Phase
Phase 2
Overall status
Terminated
Start date
July 10, 2019
Completion date
April 23, 2020
Enrollment
68 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic refractory cough